Prostamax (KEDP): Evidence, Mechanism & Legal Status

Prostamax is the trade name for a synthetic prostate-tropic short peptide — Lys-Glu-Asp-Pro (KEDP) — from Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology, positioned as the defined-sequence successor to the long-marketed Russian bovine-prostate peptide extract (Prostatilen, Vitaprost, Prostatex) used for chronic prostatitis and BPH.68 Its popularity in longevity and men's-health circles is growing; its proof as a synthetic peptide is not. This monograph separates the two.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing or buying guide. Prostamax (KEDP) is not an FDA-approved drug; it is sold as a research chemical not for human use. Dosing figures are reported strictly as described in the literature for completeness — not as recommendations. A theoretical oncologic concern applies. Consult a licensed clinician before any health decision.

What is Prostamax and how does it work?

Two distinct things share the Prostamax name, and keeping them separate is the key to reading the evidence honestly. The synthetic peptide Prostamax is a single defined-sequence tetrapeptide, Lys-Glu-Asp-Pro (KEDP), with a reported molecular formula C20H33N5O9, molecular weight about 487.5 Da, and CAS 473578-47-1, made by solid-phase synthesis — chemistry that should be treated as vendor-reported, not regulatory-grade.98 The parent Prostatilen/Vitaprost/Prostatex is something else entirely: a complex bovine-prostate peptide extract, a mixture of water-soluble prostate peptides rather than a single molecule, and the actual carrier of the human clinical history.6

The proposed mechanism — all of it mechanistic or preclinical — comes from the Khavinson bioregulation framework. The class theory holds that very short two-to-seven-residue peptides penetrate cytoplasmic and nuclear membranes, reach the nucleus, and interact sequence-specifically with double-stranded DNA promoter regions and with histones, thereby modulating chromatin compaction and gene transcription rather than blocking hormones or receptors.3 In Khavinson's own DNA-binding modelling, KEDP is tabulated among the prostate-class short peptides that bind double-stranded DNA at promoter sequences.4 The one direct Prostamax mechanistic finding is in-vitro: differential scanning calorimetry showed Prostamax shifted both chromatin denaturation endotherms in human lymphocytes to lower temperatures, consistent with partial relaxation of the 30-nm fiber — a small structural change, not a demonstrated prostate-specific transcriptional program.1 The extract's plausible prostate mechanism is more mundane and better grounded: anti-edema, anti-aggregant, microcirculation-improving and anti-inflammatory organotropic action on prostate tissue.6 No validated human pharmacokinetics, half-life or oral bioavailability exist for KEDP; short peptides are subject to gastrointestinal proteolysis and rapid plasma cleavage.3

What is the evidence by indication?

The honest summary is that there are no human RCTs of synthetic Prostamax, and the best human evidence in the entire prostate-bioregulator class is Grade B and methodologically weak — and it belongs to the extract, not the synthetic peptide.

For chronic prostatitis and CPPS, experimental rat studies of Prostamax (KEDP) report reduced tissue swelling, vascular hyperemia, lymphoid infiltration and prevention of sclerotic remodelling — but no human trial of the synthetic peptide exists.7 The human data come from the extract: a Phase IV PRESTIGE trial of Prostatex suppositories in 1,700 men with abacterial chronic prostatitis reported improvement across all NIH-CPSI domains, reduced digital-rectal-exam pain, fewer patients with elevated prostate-secretion leukocytes, and improved sexual-function scores — yet it was unblinded, single-arm and non-randomized, and the authors explicitly state that randomized, blind, placebo-controlled studies are necessary.5 Decades of Russian clinical use of Prostatilen report improvement in up to about 95% of treated patients, again without blinded or controlled design.6 The full PRESTIGE record is summarized on PubMed (PMID 37401703), which makes the single-arm, unblinded design plain.

For BPH, rodent work attributed to KEDP reports favorable effects on prostate weight and histology, but there are no human KEDP data.8 Extract reviews describe BPH symptom and urodynamic improvement, and a related Khavinson bladder bioregulator series in 28 men reported normalization of basic uroflow parameters in early-stage disease — small, open-label and single-institute, with no controlled-trial reduction in BPH progression, acute urinary retention or surgery endpoints.611 The anti-aging or epigenetic-rejuvenation narrative rests only on in-vitro lymphocyte chromatin changes — a mechanistic curiosity, not an aging or clinical outcome — and any reverses-prostate-aging or cancer-prevention framing is Grade D marketing.12

What doses appear in the literature?

Reported strictly as information, not a protocol. Because the synthetic peptide has no human trial, every dose figure for Prostamax KEDP is extrapolated, not evidence-based. Synthetic KEDP is supplied as a lyophilized powder, commonly in 20 mg vials, reconstituted with bacteriostatic water; community and vendor protocols describe roughly 5 to 10 mg subcutaneous per administration, in cycles of about 10 to 20 days, repeated one to two times per year — a pattern copied from other Khavinson-peptide protocols with no human dose-finding study behind it.109 The parent extract drugs are dosed clinically as rectal suppositories or intramuscular injection containing about 5 to 10 mg of prostate peptides, once daily for roughly 10 to 30 days, often in repeated courses; the PRESTIGE trial used one Prostatex suppository per day for 30 days.56 Oral bioregulator capsule products are pharmacologically dubious given peptide gastrointestinal digestion, and reconstituted research peptide is standard research-handling material, not a sterility-assured clinical product.9

How safe is Prostamax?

No controlled human safety dataset exists for synthetic KEDP. Safety claims of no known toxicity rest on the extract class's tolerability impression and on the general low-dose short-peptide rationale, not on rigorous adverse-event capture, which is a known weakness of the Russian bioregulator literature.63 Reported or plausible adverse events include injection-site reactions and hypersensitivity, with suppository forms causing local irritation; the PRESTIGE report described the extract as well tolerated, but with weak adverse-event methodology.5 The dominant theoretical concern deserves to be taken seriously: a peptide proposed to remodel chromatin and shift gene expression in proliferative glandular tissue carries a theoretical risk of promoting unwanted proliferation, and vendors themselves carry a carcinogenic-risk flag advising oncologist consultation if prostate cancer is present.9 Because BPH and early prostate cancer can coexist and present similarly, using an unproven proliferation-modulating peptide without a malignancy work-up is imprudent. As a gray-market research chemical, real-world risk is also dominated by identity, purity, endotoxin and sterility uncertainty in non-pharmaceutical product.12 It is contraindicated with known prostate malignancy or undiagnosed elevated PSA or abnormal DRE, and with hypersensitivity; pregnancy, lactation and pediatric use are not applicable to this male prostate indication and entirely untested.

What is the FDA and WADA status in 2026?

Prostamax (KEDP) is not an FDA-approved drug for any indication and has no approved labeling. It is not an approved bulk drug substance for pharmacy compounding under 503A or 503B, and the broader Khavinson short-peptide class has faced FDA tightening, with multiple longevity and bioregulator peptides moved off the interim 503A Category 2 list in 2026 and remaining unsanctioned for compounding.12 It is therefore sold in the United States only as a research chemical not for human use, and purchasing or using research-only peptides for human consumption violates FDA rules.9 Synthetic KEDP is also not a lawful dietary ingredient under DSHEA, so supplement marketing is non-compliant.12 By contrast, the extract products Prostatilen and Vitaprost are registered medicines used clinically for decades in Russia and the CIS, but the synthetic KEDP Prostamax does not carry equivalent Western approval.6

For athletes, Prostamax/KEDP is not explicitly named on the WADA Prohibited List, but any pharmacological substance with no approval for human therapeutic use can be captured by category S0 (Non-Approved Substances) and is prohibited at all times — so athletes should treat it as banned, with no ergogenic rationale to justify the risk.13 It is not a controlled substance under the DEA.

Bottom line. Prostamax pairs a biologically plausible, well-tolerated concept with a near-total absence of synthetic-peptide proof. There is genuine, if low-grade, human signal for the extract in prostatitis, but the synthetic Prostamax peptide as sold is preclinical-grade and legally a research chemical, not a validated therapy. The class is single-lineage, unblinded, non-randomized and not independently replicated in the West, with no human pharmacokinetics, no dose-finding, no controlled safety data and a theoretical oncology concern. Regulatory facts here are current as of June 2026 and should be re-verified for any later compounding or anti-doping decision.